‘Leiden’ vaccine enters large-scale testing phase, looking for 60,000 volunteers

The disputed religious vote in the US elections

There may have been no less religious president in modern America than Donald Trump, no matter how much he declares himself a Presbyterian Protestant....

It has not been seen in public for 9 months

The hermetic and not very transparent communist regime in North Korea gives rise to every little information about disappearances from the public eye of...

The number of positive tests in Belgium continues to increase rapidly, especially in Liège

The number of positive corona tests in Belgium has increased sharply again in the past week, according to figures from the online dashboard of...

The war in the Caucasus. Pompeo receives his Azerbaijani and Armenian counterparts in Washington: Call for an end to violence and diametrically opposed...

Mike Pompeo met separately in Washington with his Azerbaijani counterpart Djeyhun Bairamov and then with Armenian Zohrab Mnatakanian. The head of US diplomacy "stressed the...

AstraZeneca and Johnson & Johnson resume trials of corona vaccines

AstraZeneca and Johnson & Johnson are resuming their trials in the United States with the corona vaccines they have developed. As a precaution,...

The corona vaccine that is being developed by Janssen Vaccines from Leiden, a subsidiary of the American pharmaceutical company Johnson & Johnson, is entering a large-scale test phase. In the so-called third test phase, tens of thousands of volunteers are administered the drug to monitor side effects.

Johnson & Johnson aims to produce a billion doses next year

The European Union has ordered hundreds of millions of doses of the drug, but has also purchased hundreds of millions of doses from other vaccine developers. Some resources have already entered a large-scale test phase earlier.

Johnson & Johnson aims to test at least 60,000 people over the age of 18 in the United States, South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. All countries have been statistically severely affected by the COVID-19 outbreak.

The test phase must be completed within two months. Johnson & Johnson hopes to publish results at the end of this year or early next year.

The pharmaceutical company hopes to be able to test large numbers of elderly people. If the test results are again promising, Johnson & Johnson wants to take the next step in the production process. Next year, the American company wants to develop a billion doses.

Experts are hopeful about the Johnson & Johnson vaccine, partly because the company is focusing on one dose instead of the regular two doses, as with AstraZeneca, for example.

Using one dose only allows interested parties to schedule one appointment to be vaccinated, and also simplifies the worldwide distribution of the drug. The vaccine would also have a better shelf life.



Related Articles